Myndscope employs a combination of structure-activity relationship (SAR) based drug screening, which is typically used for screening inhibitors of enzymes or proteins having an active site, in conjunction with small molecules capable of changing surface chemistry through which the small molecule will modify the targeted protein’s interactions with other proteins. As a result, the targeted protein could either interact with neosubstrates, i.e, substrates it would not interact with under normal circumstances, or stop interacting with its normal substrates. Conceptually, these changes in the pool of interaction partners would bring about intended therapeutic benefits. We have currently pursuing pre-clinical validation of several small molecules that can change interaction dynamics in the brain, which in our animal model studies turned out to be helpful in not only alleviating the symptoms of tested diseases, but also reducing the causes of the diseases at molecular level. To date, several compounds have shown efficacy for Parkinson’s disease, Alzheimer’s disease, and PTSD, respectively.
Neuroscience at its best